Aetna, a CVS Health Company

aetna.com

Here at Aetna, a CVS Health business, we are building a healthier world by making healthcare easy, affordable and all about you. Follow our LinkedIn page for company news, industry commentary, jobs and more. Founded in 1853 in Hartford, CT, Aetna is one of the nation's leading diversified health care benefits companies, serving an estimated 46.7 million people with information and resources to help them make better decisions about their healthcare.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

AI

LABCORP AND PATHAI EXPAND THEIR PARTNERSHIP TO ACCELERATE USE OF AI-POWERED PATHOLOGY

PathAI, Labcorp | March 09, 2021

news image

PathAI, a global supplier of artificial intelligence-powered (AI-powered) innovation for use in pathology research, and Labcorp, a main global life sciences company, today declared the expanding of their essential organization in the field of AI-powered pathology. The coordinated effort expands on Labcorp's past investment in PathAI and the companies' cooperation on a progression of projects, remembering the deployment of PathAI algorithms for clinical trials oversaw by Labcorp Drug Deve...

Read More

CELL AND GENE THERAPY

NEW RESEARCH FROM THE CARIS PRECISION ONCOLOGY ALLIANCE FINDS PROGNOSTIC AND PREDICTIVE DRUG-INDUCED GENE SIGNATURES FOR COLORECTAL CANCER PATIENTS

Caris Life Sciences | April 11, 2022

news image

Caris Life Sciences®(Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, to present findings that provide a deeper understanding that tumor expression of genes related to extent of drug exposure, stratified by p53 status, is associated with clinical outcomes on the common chemotherapeutic regimens used to treat metastatic colorectal cancer (CRC). These results will be presented at the 2022 American ...

Read More

EDITING TECHNOLOGY TO IDENTIFY AND ADVANCE GENETIC DYSFUNCTION THERAPIES

BlueAllele | July 27, 2020

news image

BlueAllele, a biotechnology company focused on enhancing the quality and precision of gene editing systems for patients with genetic diseases, announced the launch of PALIDON™, an innovative and proprietary repair template technology.Many rare genetic diseases are caused by mutations within a single gene. However, the location of the mutation often varies for different individuals with the same disease. Conventional gene editing approaches are primarily limited to correcting small re...

Read More

MEDTECH

SEQUENCE BIO ANNOUNCES DISCOVERY COLLABORATION AGREEMENT WITH LEO PHARMA

Sequence Bio | April 08, 2022

news image

Sequence Bio, a Newfoundland and Labrador-based discovery biology company, announced today that it has entered into a collaboration agreement with Danish dermatology specialists LEO Pharma, for use of Sequence Bio's proprietary discovery platform to identify novel dermatologic drug targets. Under the terms of the three year agreement, Sequence Bio will perform multi-omic analyses of samples from powered discovery cohorts across multiple dermatologic indications. LEO Pharma will leverage insi...

Read More
news image

AI

LABCORP AND PATHAI EXPAND THEIR PARTNERSHIP TO ACCELERATE USE OF AI-POWERED PATHOLOGY

PathAI, Labcorp | March 09, 2021

PathAI, a global supplier of artificial intelligence-powered (AI-powered) innovation for use in pathology research, and Labcorp, a main global life sciences company, today declared the expanding of their essential organization in the field of AI-powered pathology. The coordinated effort expands on Labcorp's past investment in PathAI and the companies' cooperation on a progression of projects, remembering the deployment of PathAI algorithms for clinical trials oversaw by Labcorp Drug Deve...

Read More
news image

CELL AND GENE THERAPY

NEW RESEARCH FROM THE CARIS PRECISION ONCOLOGY ALLIANCE FINDS PROGNOSTIC AND PREDICTIVE DRUG-INDUCED GENE SIGNATURES FOR COLORECTAL CANCER PATIENTS

Caris Life Sciences | April 11, 2022

Caris Life Sciences®(Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, to present findings that provide a deeper understanding that tumor expression of genes related to extent of drug exposure, stratified by p53 status, is associated with clinical outcomes on the common chemotherapeutic regimens used to treat metastatic colorectal cancer (CRC). These results will be presented at the 2022 American ...

Read More
news image

EDITING TECHNOLOGY TO IDENTIFY AND ADVANCE GENETIC DYSFUNCTION THERAPIES

BlueAllele | July 27, 2020

BlueAllele, a biotechnology company focused on enhancing the quality and precision of gene editing systems for patients with genetic diseases, announced the launch of PALIDON™, an innovative and proprietary repair template technology.Many rare genetic diseases are caused by mutations within a single gene. However, the location of the mutation often varies for different individuals with the same disease. Conventional gene editing approaches are primarily limited to correcting small re...

Read More
news image

MEDTECH

SEQUENCE BIO ANNOUNCES DISCOVERY COLLABORATION AGREEMENT WITH LEO PHARMA

Sequence Bio | April 08, 2022

Sequence Bio, a Newfoundland and Labrador-based discovery biology company, announced today that it has entered into a collaboration agreement with Danish dermatology specialists LEO Pharma, for use of Sequence Bio's proprietary discovery platform to identify novel dermatologic drug targets. Under the terms of the three year agreement, Sequence Bio will perform multi-omic analyses of samples from powered discovery cohorts across multiple dermatologic indications. LEO Pharma will leverage insi...

Read More